(NASDAQ: ALKS) Alkermes's forecast annual revenue growth rate of 10.07% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.93%.
Alkermes's revenue in 2026 is $1,562,300,000.On average, 19 Wall Street analysts forecast ALKS's revenue for 2026 to be $307,850,215,529, with the lowest ALKS revenue forecast at $291,849,338,057, and the highest ALKS revenue forecast at $325,017,823,650. On average, 19 Wall Street analysts forecast ALKS's revenue for 2027 to be $319,350,846,212, with the lowest ALKS revenue forecast at $268,348,049,270, and the highest ALKS revenue forecast at $388,521,306,117.
In 2028, ALKS is forecast to generate $351,185,925,349 in revenue, with the lowest revenue forecast at $306,683,484,880 and the highest revenue forecast at $466,192,232,179.